{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T04:47:12Z","timestamp":1768279632387,"version":"3.49.0"},"reference-count":108,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1016\/j.biopha.2006.09.007","type":"journal-article","created":{"date-parts":[[2006,10,21]],"date-time":"2006-10-21T07:11:23Z","timestamp":1161414683000},"page":"678-687","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["The use of\u00a0low dose methotrexate in\u00a0rheumatoid arthritis\u2014are we entering a\u00a0new era of\u00a0therapeutic drug monitoring and\u00a0pharmacogenomics?"],"prefix":"10.1016","volume":"60","author":[{"given":"Lisa","family":"Stamp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murray","family":"Barclay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2006.09.007_bib1","first-page":"417","article-title":"Patterns of radiological progression in early rheumatoid arthritis: results of an 8-year prospective study","volume":"25","author":"Plant","year":"1998","journal-title":"J. Rheumatol."},{"issue":"Suppl 2","key":"10.1016\/j.biopha.2006.09.007_bib2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/rheumatology\/XXXIV.suppl_2.74","article-title":"Joint erosions and patients with early rheumatoid arthritis","volume":"34","author":"van der Heijde","year":"1995","journal-title":"Br. J. Rheumatol."},{"issue":"9","key":"10.1016\/j.biopha.2006.09.007_bib3","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/1529-0131(199809)41:9<1571::AID-ART7>3.0.CO;2-R","article-title":"Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression","volume":"41","author":"Wolfe","year":"1998","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.biopha.2006.09.007_bib4","first-page":"47","article-title":"Inflammatory patterns in rheumatoid arthritis estimated by the number of swollen and tender joints, the erythrocyte sedimentation rate and hemoglobin: long-term course and association to radiographic progression","volume":"27","author":"Graudal","year":"2000","journal-title":"J. Rheumatol."},{"issue":"6","key":"10.1016\/j.biopha.2006.09.007_bib5","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/1529-0131(199806)41:6<1072::AID-ART14>3.0.CO;2-G","article-title":"The long-term outcomes of rheumatoid arthritis. A 23-year prospective, longitudinal study of total joint replacement and its predictors in 1600 patients with rheumatoid arthritis","volume":"41","author":"Wolfe","year":"1998","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.biopha.2006.09.007_bib6","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1002\/1529-0131(199909)42:9<1854::AID-ANR9>3.0.CO;2-F","article-title":"Long-term course and outcome of functional capacity in rheumatoid arthritis","volume":"42","author":"Drossaers-Bakker","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2006.09.007_bib7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.biopha.2006.09.007_bib8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U","article-title":"Treatment with leflunomide slows radiographic progression of rheumatoid arthritis","volume":"43","author":"Sharp","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2006.09.007_bib9","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/rheumatology\/40.11.1243","article-title":"Association of clinical, radiological and synovial immunopathological responses to anti-rheumatic treatment in rheumatoid arthritis","volume":"40","author":"Pettit","year":"2001","journal-title":"Rheumatol."},{"key":"10.1016\/j.biopha.2006.09.007_bib10","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/ard.60.8.729","article-title":"Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis","volume":"60","author":"Cutolo","year":"2001","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2006.09.007_bib11","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/rheumatology\/28.5.422","article-title":"Synovial and serum levels of methotrexate during methotrexate therapy of rheumatoid arthritis","volume":"28","author":"Tishler","year":"1989","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.biopha.2006.09.007_bib12","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1016\/0006-2952(87)90651-4","article-title":"Influence of intracellular folates on methotrexate metabolism and cytotoxicity","volume":"36","author":"Jolivet","year":"1987","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2006.09.007_bib13","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1016\/0006-2952(85)90013-9","article-title":"The effect of leucovorin on the synthesis of methotrexate polygammaglutamates in the MCF-7 human breast cancer cell line","volume":"34","author":"Kennedy","year":"1985","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2006.09.007_bib14","first-page":"302","article-title":"Safety of self-injection of gold and methotrexate","volume":"26","author":"Arthur","year":"1999","journal-title":"J. Rheumatol."},{"issue":"4","key":"10.1016\/j.biopha.2006.09.007_bib15","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1136\/ard.60.4.432","article-title":"Is parenteral methotrexate worth trying?","volume":"60","author":"Osman","year":"2001","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2006.09.007_bib16","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/ard.60.12.1156","article-title":"Intramuscular methotrexate in inflammatory rheumatic disease","volume":"60","author":"Burbage","year":"2001","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2006.09.007_bib17","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/rheumatology\/keg246","article-title":"Parenteral methotrexate should be given before biological therapy","volume":"42","author":"Bingham","year":"2003","journal-title":"Rheumatol."},{"key":"10.1016\/j.biopha.2006.09.007_bib18","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/ard.2003.011593","article-title":"Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis","volume":"63","author":"Wegrzyn","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2006.09.007_bib19","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1136\/ard.61.8.756","article-title":"Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate","volume":"61","author":"Rozin","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2006.09.007_bib20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/rheumatology\/36.1.86","article-title":"Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis","volume":"36","author":"Hamilton","year":"1997","journal-title":"Br. J. Rheumatol."},{"issue":"9 Suppl","key":"10.1016\/j.biopha.2006.09.007_bib21","first-page":"S542","article-title":"The clinical efficacy and safety of subcutaneous versus oral application of methotrexate in patients with active rheumatoid arthritis\u2014results of a randomised, controlled, double-blind multicenter study","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.biopha.2006.09.007_bib22","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/art.20167","article-title":"Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate","volume":"50","author":"Lambert","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.biopha.2006.09.007_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/art.1780330112","article-title":"Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis","volume":"33","author":"Brooks","year":"1990","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2006.09.007_bib24","first-page":"1845","article-title":"A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing","volume":"20","author":"Jundt","year":"1993","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.biopha.2006.09.007_bib25","first-page":"481","article-title":"Splitting high dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis","volume":"33","author":"Hoekstra","year":"2006","journal-title":"J. Rheumatol."},{"issue":"4","key":"10.1016\/j.biopha.2006.09.007_bib26","doi-asserted-by":"crossref","first-page":"489","DOI":"10.7326\/0003-4819-103-4-489","article-title":"Weekly pulse methotrexate in rheumatoid arthritis","volume":"103","author":"Anderson","year":"1985","journal-title":"Ann. Intern. Med."},{"issue":"7","key":"10.1016\/j.biopha.2006.09.007_bib27","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/art.1780280702","article-title":"Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis","volume":"28","author":"Williams","year":"1985","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.biopha.2006.09.007_bib28","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/art.1780350203","article-title":"Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis","volume":"35","author":"Kremer","year":"1992","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.biopha.2006.09.007_bib29","first-page":"263","article-title":"Influence of methotrexate on radiographic progression in rheumatoid arthritis: a sixty month prospective study","volume":"15","author":"Drosos","year":"1997","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"10.1016\/j.biopha.2006.09.007_bib30","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/1529-0131(199909)42:9<1870::AID-ANR11>3.0.CO;2-D","article-title":"Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis","volume":"42","author":"Strand","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2006.09.007_bib31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/archinte.1990.00390130073009","article-title":"Methotrexate in rheumatoid arthritis: impact on quality of life assessed by traditional standard-item and individualised patient preference health status questionnaires","volume":"150","author":"Tugwell","year":"1990","journal-title":"Arch. Intern. Med."},{"issue":"20","key":"10.1016\/j.biopha.2006.09.007_bib32","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM199605163342002","article-title":"Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hyroxychloroquine or a combination of all three medications","volume":"334","author":"O\u2019Dell","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2006.09.007_bib33","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/art.21018","article-title":"A 48-week, randomized, double-blind, double-observer, placebo controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis","volume":"52","author":"Lehman","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2006.09.007_bib34","doi-asserted-by":"crossref","first-page":"726","DOI":"10.7326\/0003-4819-137-9-200211050-00007","article-title":"Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate","volume":"137","author":"Kremer","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.biopha.2006.09.007_bib35","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2006.09.007_bib36","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2006.09.007_bib37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully humanised anti-tumor necrosis factor \u03b1 monoclonal antibody for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.biopha.2006.09.007_bib38","first-page":"704","article-title":"Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice","volume":"19","author":"Morand","year":"1992","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.biopha.2006.09.007_bib39","first-page":"CD000952","article-title":"Methotrexate for treating rheumatoid arthritis","volume":"2","author":"Suarez-Almazor","year":"2000","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.biopha.2006.09.007_bib40","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/anr.1780320603","article-title":"Methotrexate in rheumatoid arthritis: toxic effects as the major factor in limiting long-term treatment","volume":"32","author":"Alarcon","year":"1989","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.biopha.2006.09.007_bib41","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/art.1780371013","article-title":"Methotrexate in rheumatoid arthritis: a five-year prospective multicenter study","volume":"37","author":"Weinblatt","year":"1994","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2006.09.007_bib42","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/rheumatology\/39.9.975","article-title":"Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs","volume":"39","author":"Maetzel","year":"2000","journal-title":"Rheumatol."},{"issue":"5","key":"10.1016\/j.biopha.2006.09.007_bib43","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/0049-0172(94)90027-2","article-title":"Low-dose methotrexate in rheumatic diseases\u2014efficacy, side effects, and risk factors for side effects","volume":"23","author":"Schnabel","year":"1994","journal-title":"Semin. Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.biopha.2006.09.007_bib44","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/art.1780390214","article-title":"Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis","volume":"39","author":"Gutierrez-Urena","year":"1996","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.biopha.2006.09.007_bib45","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/anr.1780321214","article-title":"Elevated mean corpuscular volume as a predictor of haematologic toxicity due to methotrexate therapy","volume":"31","author":"Weinblatt","year":"1989","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2006.09.007_bib46","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1002\/elps.200410403","article-title":"Review of denaturant capillary electrophoresis in DNA variation analysis","volume":"26","author":"Bjorheim","year":"2005","journal-title":"Electrophoresis"},{"issue":"3","key":"10.1016\/j.biopha.2006.09.007_bib47","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.biopha.2006.09.007_bib48","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/anr.1780320202","article-title":"Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples","volume":"32","author":"Kremer","year":"1989","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2006.09.007_bib49","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/03009749950155454","article-title":"Elevation of serum hepatic aminotransferases during treatment of rheumatoid arthritis with low dose methotrexate","volume":"28","author":"Suzuki","year":"1999","journal-title":"Scand J Rheum"},{"key":"10.1016\/j.biopha.2006.09.007_bib50","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0002-9343(05)80060-9","article-title":"Methotrexate and histologic hepatic abnormalities: a meta-analysis","volume":"90","author":"Whiting-O\u2019Keefe","year":"1991","journal-title":"Am. J. Med."},{"issue":"3","key":"10.1016\/j.biopha.2006.09.007_bib51","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/art.1780360307","article-title":"Determinants of serious liver disease among patients receiving low dose methotrexate for rheumatoid arthritis","volume":"36","author":"Walker","year":"1992","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.biopha.2006.09.007_bib52","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/art.1780370304","article-title":"Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity","volume":"37","author":"Kremer","year":"1994","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.biopha.2006.09.007_bib53","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/art.10148","article-title":"Guidelines for the management of rheumatoid arthritis","volume":"46","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2006.09.007_bib54","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/ard.53.7.434","article-title":"Methotrexate related pulmonary complications in rheumatoid arthritis","volume":"53","author":"Barrera","year":"1994","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.biopha.2006.09.007_bib55","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/art.1780401016","article-title":"Clinical, laboratory, radiographic and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis","volume":"40","author":"Kremer","year":"1997","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2006.09.007_bib56","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/qjmed\/94.6.309","article-title":"Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice","volume":"94","author":"Grove","year":"2001","journal-title":"Q. J. Med."},{"key":"10.1016\/j.biopha.2006.09.007_bib57","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/rheumatology\/keg466","article-title":"Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis","volume":"43","author":"Saravanan","year":"2004","journal-title":"Rheumatol."},{"key":"10.1016\/j.biopha.2006.09.007_bib58","doi-asserted-by":"crossref","first-page":"356","DOI":"10.7326\/0003-4819-127-5-199709010-00003","article-title":"Risk factors for methotrexate induced lung disease in patients with rheumatoid arthritis: a multicentre, case-controlled study","volume":"127","author":"Alarcon","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.biopha.2006.09.007_bib59","first-page":"1164","article-title":"Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and review of the literature","volume":"14","author":"Searles","year":"1987","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.biopha.2006.09.007_bib60","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1034\/j.1399-3003.2000.15b25.x","article-title":"Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients","volume":"15","author":"Imokawa","year":"2000","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.biopha.2006.09.007_bib61","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/art.1780350202","article-title":"Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis 84-month update","volume":"35","author":"Weinblatt","year":"1992","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.biopha.2006.09.007_bib62","first-page":"867","article-title":"Accelerated nodulosis during low dose methotrexate therapy for rheumatoid arthritis","volume":"19","author":"Kerstens","year":"1992","journal-title":"J. Rheumatol."},{"issue":"7","key":"10.1016\/j.biopha.2006.09.007_bib63","first-page":"1308","article-title":"Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate induced nodulosis in rheumatoid arthritis","volume":"40","author":"Merrill","year":"1997","journal-title":"Arthritis Rheum."},{"issue":"3 pt 1","key":"10.1016\/j.biopha.2006.09.007_bib64","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S0002-9378(98)70052-3","article-title":"Methotrexate effects on trophoblast and the corpus luteum in early pregnancy","volume":"179","author":"Creinin","year":"1998","journal-title":"Am J Obstet. Gynecol."},{"key":"10.1016\/j.biopha.2006.09.007_bib65","first-page":"1872","article-title":"Low dose weekly methotrexate in early pregnancy. A case series and review of the literature","volume":"27","author":"Ostensen","year":"2000","journal-title":"J. Rheumatol."},{"issue":"1","key":"10.1016\/j.biopha.2006.09.007_bib66","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/art.1780330102","article-title":"The effect of folic acid supplementation of the toxicity of low-dose methotrexate in patients with rheumatoid arthritis","volume":"33","author":"Morgan","year":"1990","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.biopha.2006.09.007_bib67","first-page":"36","article-title":"The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A meta analysis of randomized controlled trials","volume":"25","author":"Ortiz","year":"1998","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.biopha.2006.09.007_bib68","first-page":"CD000951","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","volume":"2","author":"Ortiz","year":"2000","journal-title":"Cochrane Database Syst. Rev."},{"issue":"11","key":"10.1016\/j.biopha.2006.09.007_bib69","doi-asserted-by":"crossref","first-page":"833","DOI":"10.7326\/0003-4819-121-11-199412010-00002","article-title":"Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis","volume":"121","author":"Morgan","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.biopha.2006.09.007_bib70","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/rheumatology\/39.10.1102","article-title":"Do patients with rheumatoid arthritis established on methotrexate and folic acid 5\u00a0mg daily need to continue folic acid supplements long term?","volume":"39","author":"Griffith","year":"2000","journal-title":"Rheumatol."},{"issue":"7","key":"10.1016\/j.biopha.2006.09.007_bib71","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7","article-title":"Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis","volume":"44","author":"van Ede","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2006.09.007_bib72","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/ard.62.5.423","article-title":"Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis","volume":"62","author":"Hoekstra","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2006.09.007_bib73","first-page":"1727","article-title":"Risk factors for methotrexate induced abnormal monitoring results in patients with rheumatoid arthritis","volume":"31","author":"Kent","year":"2004","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.biopha.2006.09.007_bib74","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.forsciint.2004.12.031","article-title":"Iatrogenically-related fatal methotrexate intoxication: a series of four cases","volume":"156","author":"Moisa","year":"2006","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.biopha.2006.09.007_bib75","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/bmj.326.7383.266","article-title":"Low dose methotrexate and bone marrow suppression","volume":"326","author":"Sosin","year":"2003","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.biopha.2006.09.007_bib76","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/art.10280","article-title":"Folic acid and folinic acid supplementation during low dose methotrexate therpay for rheumatoid arthritis: comment on article by van Ede et al","volume":"46","author":"Morgan","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.biopha.2006.09.007_bib77","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1002\/art.21295","article-title":"Reduction in efficacy of methotrexate by the use of folic acid. Post hoc analysis from two randomised controlled studies","volume":"52","author":"Khanna","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2006.09.007_bib78","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1136\/ard.2004.033399","article-title":"Pharmacogenetic and metabolite measurements are associated with clinical status in rheumatoid arthritis patients treated with methotrexate: results of a multicentered cross sectional observational study","volume":"64","author":"Dervieux","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2006.09.007_bib79","first-page":"313","article-title":"Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis","volume":"16","author":"Furst","year":"1989","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.biopha.2006.09.007_bib80","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/rheumatology\/32.8.751","article-title":"Preliminary report: methotrexate\u2014the relationship between dose and clinical effect","volume":"32","author":"Seidman","year":"1993","journal-title":"Br. J. Rheumatol."},{"issue":"9","key":"10.1016\/j.biopha.2006.09.007_bib81","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1002\/art.20460","article-title":"Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis","volume":"50","author":"Dervieux","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.biopha.2006.09.007_bib82","first-page":"844","article-title":"Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis","volume":"22","author":"Lafforgue","year":"1995","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.biopha.2006.09.007_bib83","first-page":"313","article-title":"Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis","volume":"17","author":"Angelis-Stoforidis","year":"1999","journal-title":"Clin. Exp. Rheumatol."},{"issue":"Suppl","key":"10.1016\/j.biopha.2006.09.007_bib84","first-page":"350","article-title":"Measurement of erythrocyte methotrexate polyglutamates predicts response to methotrexate therapy in a dose escalation study with rheumatoid arthritis patients","volume":"50","author":"Kremer","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2006.09.007_bib85","first-page":"749","article-title":"Technology platforms for pharmacogenomic diagnostic assays","volume":"3","author":"Koch","year":"2004","journal-title":"Nature Rev"},{"key":"10.1016\/j.biopha.2006.09.007_bib86","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.mrfmmm.2005.01.004","article-title":"Advances in sequencing technology","volume":"573","author":"Chan","year":"2005","journal-title":"Mutat. Res."},{"issue":"5","key":"10.1016\/j.biopha.2006.09.007_bib87","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.21762","article-title":"Methotrexate pharmacogenetics. The first step towards individualised therapy in rheumatoid arthritis","volume":"54","author":"Ranganathan","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.biopha.2006.09.007_bib88","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/art.21573","article-title":"Risk genotypes in folate-dependent enzymes and their association with methotrexate related side effects in rheumatoid arthritis","volume":"54","author":"Weisman","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.biopha.2006.09.007_bib89","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1517\/14622416.5.5.559","article-title":"Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis","volume":"5","author":"Ranganathan","year":"2004","journal-title":"Pharmacogenomics"},{"issue":"9","key":"10.1016\/j.biopha.2006.09.007_bib90","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1136\/ard.2005.046797","article-title":"Racial\/ethnic differences in allele frequencies of single nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence in response to methotrexate in rheumatoid arthritis","volume":"65","author":"Hughes","year":"2006","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.biopha.2006.09.007_bib91","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/00008571-200411000-00004","article-title":"Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis","volume":"14","author":"Dervieux","year":"2004","journal-title":"Pharmacogenetics"},{"issue":"9","key":"10.1016\/j.biopha.2006.09.007_bib92","doi-asserted-by":"crossref","first-page":"496","DOI":"10.5414\/CPP42496","article-title":"The MDR1 3435 polymorphism in patients with rheumatoid arthritis","volume":"42","author":"Pawlik","year":"2004","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2006.09.007_bib93","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01213011-200505000-00002","article-title":"A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination","volume":"15","author":"Hulot","year":"2005","journal-title":"Pharmacogenet. Genomics"},{"issue":"11","key":"10.1016\/j.biopha.2006.09.007_bib94","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1002\/1529-0131(200111)44:11<2525::AID-ART432>3.0.CO;2-B","article-title":"The C677T mutation in the methylenetetrahydrofolate reductase gene. A risk factor for methotrexate-related elevation of liver emzymes in rheumatoid arthritis patients","volume":"44","author":"van Ede","year":"2001","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.biopha.2006.09.007_bib95","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/art.21726","article-title":"Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes","volume":"54","author":"Wessels","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2006.09.007_bib96","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1136\/ard.2005.037218","article-title":"Relationship between 5,10-methylenetetrahydrofolate reductase C677T gene polymorphism and methotrexate related toxicity in patients with autoimmune diseases receiving folic acid supplementation","volume":"64","author":"Speletas","year":"2005","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.biopha.2006.09.007_bib97","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1093\/annonc\/mdf322","article-title":"Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate","volume":"13","author":"Chiusolo","year":"2002","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2006.09.007_bib98","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1182\/blood.V98.1.231","article-title":"Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism","volume":"98","author":"Ulrich","year":"2001","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.biopha.2006.09.007_bib99","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00008571-200204000-00002","article-title":"Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses","volume":"12","author":"Urano","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.biopha.2006.09.007_bib100","first-page":"593","article-title":"Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis","volume":"11","author":"Kumagai","year":"2003","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.biopha.2006.09.007_bib101","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1136\/ard.2003.016337","article-title":"Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene","volume":"63","author":"Berkun","year":"2004","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.biopha.2006.09.007_bib102","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/00008571-200405000-00007","article-title":"A 6\u00a0bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels","volume":"14","author":"Mandola","year":"2004","journal-title":"Pharmacogenetics"},{"issue":"7","key":"10.1016\/j.biopha.2006.09.007_bib103","first-page":"1952","article-title":"A novel single-nucleotide polymorphism in the 3\u2032-untranslated region of the human dihydrofolate reductase gene with enhanced expression","volume":"7","author":"Goto","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2006.09.007_bib104","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0378-1119(03)00807-2","article-title":"Identification of single nucleotide polymorphisms in the human gamma-glutamyl hydrolase gene and characterization of promoter polymorphisms","volume":"319","author":"Chave","year":"2003","journal-title":"Gene"},{"issue":"2","key":"10.1016\/j.biopha.2006.09.007_bib105","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/blood-2004-12-4941","article-title":"Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia","volume":"106","author":"de Jonge","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.biopha.2006.09.007_bib106","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1006\/mgme.2001.3175","article-title":"Is mutated serine hydroxymethyltransferase (SHMT) involved in the etiology of neural tube defects?","volume":"73","author":"Heil","year":"2001","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.biopha.2006.09.007_bib107","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"The American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.biopha.2006.09.007_bib108","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","article-title":"Development and validation of the European League against rheumatism response criteria for rheumatoid arthritis","volume":"39","author":"Van Gestel","year":"1996","journal-title":"Arthritis Rheum."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332206002927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332206002927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:38:10Z","timestamp":1760092690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332206002927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":108,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["S0753332206002927"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2006.09.007","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use of\u00a0low dose methotrexate in\u00a0rheumatoid arthritis\u2014are we entering a\u00a0new era of\u00a0therapeutic drug monitoring and\u00a0pharmacogenomics?","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2006.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}